LIF and breast carcinoma: To further verify the effect of breast cancer-derived CXCLs on the expression of LIF in CAAs and its upstream signaling pathway, the neutralizing antibody of CXCL3 (α-CXCL3) was used in the co-culture system to evaluate the expression level of LIF.